Sierra Oncology, Inc. Common Stock
SRRA
SRRA was delisted on the 30th of June, 2022.
42 hedge funds and large institutions have $18.7M invested in Sierra Oncology, Inc. Common Stock in 2016 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 12 increasing their positions, 9 reducing their positions, and 10 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 9
5% less funds holding
Funds holding: 44 → 42 (-2)
20% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 10
27% less capital invested
Capital invested by funds: $25.7M → $18.7M (-$7.07M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$542K |
| 2 |
Renaissance Technologies
New York
|
+$436K |
| 3 |
JP Morgan Chase
New York
|
+$312K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$300K |
| 5 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
+$205K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
-$4.3M |
| 2 |
ASP
Adams Street Partners
Chicago,
Illinois
|
-$1.47M |
| 3 |
DM
Deerfield Management
New York
|
-$428K |
| 4 |
QF
QVT Financial
New York
|
-$139K |
| 5 |
AA
Ancora Advisors
Cleveland,
Ohio
|
-$132K |
SRRA Hedge Fund Activity: Q3 2016 in Review
42 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Sierra Oncology, Inc. Common Stock (SRRA) for Q3 2016, worth a combined $18.7M — down 27% from $25.7M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of SRRA and 8 opened new positions — a net loss of 2 holders — while 9 trimmed existing stakes and 12 added.
The largest buyer was Bridgeway Capital Management, adding an estimated $542K. The largest seller was Pictet Asset Management (UK), exiting entirely with an estimated $4.3M sold.
- 42 institutional investors held Sierra Oncology, Inc. Common Stock (SRRA) as of Q3 2016, down from 44 in Q2 2016.
- Funds reported $18.7M of Sierra Oncology, Inc. Common Stock stock for Q3 2016, down 27% quarter-over-quarter.
- 8 funds opened new Sierra Oncology, Inc. Common Stock positions in Q3 2016 and 10 closed out, a net change of -2 holders.
- The largest Sierra Oncology, Inc. Common Stock buyer in Q3 2016 was Bridgeway Capital Management, an estimated $542K added.
- The largest Sierra Oncology, Inc. Common Stock seller in Q3 2016 was Pictet Asset Management (UK), an estimated $4.3M sold.
Based on aggregated 13F filings for Q3 2016.